ALKEM \u2014 Recent Activity

India Opened the Floodgates on Weight-Loss Generics

Indian pharma companies are releasing over 50 generic versions of Ozempic and Wegovy at eye-watering prices of $14 a month.

Click to open →

Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India

By Rishika Sadam HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's patent on semaglutide expires this week,

Click to open →

Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements

Esperion Therapeutics Inc (NASDAQ:ESPR) is among the best NASDAQ penny stocks to buy according to analysts. On February 17, Esperion Therapeutics Inc (NASDAQ:ESPR) struck a deal with Alkem Laboratories regarding the sale of rival generic drugs. Specifically, Esperion got Alkem to agree that it would not sell generic versions of Esperion’s drugs NEXLETOL and NEXLIZET […]

Click to open →

Axsome Therapeutics (AXSM) Valuation After SUNOSI Patent Settlement Extends Generic Entry Timeline

Axsome Therapeutics (AXSM) shares are in focus after the company settled patent litigation with Alkem Laboratories over its SUNOSI product, setting licensed generic entry dates starting in 2040, subject to regulatory approvals. See our latest analysis for Axsome Therapeutics. The legal settlement arrives after a strong run in the shares, with a 90 day share price return of 24.89% and a 1 year total shareholder return of 43.10%, suggesting momentum has been building over both shorter and...

Click to open →

Axsome Patent Settlement Shapes SUNOSI Outlook And Valuation Debate

Axsome Therapeutics and Alkem Laboratories have reached a patent litigation settlement related to a proposed generic version of SUNOSI. The agreement sets a licensed U.S. entry date for Alkem's generic SUNOSI, subject to regulatory approval and standard legal reviews. Separate patent litigation with another party over SUNOSI remains ongoing. Axsome Therapeutics, listed as NasdaqGM:AXSM, is drawing attention as it works to protect SUNOSI, one of its commercial products, through this...

Click to open →

Alkem Laboratories Ltd (BOM:539523) Q3 2026 Earnings Call Highlights: Strong International ...

Alkem Laboratories Ltd (BOM:539523) reports a 10.7% YoY revenue growth, driven by international sales, while facing profitability pressures and strategic expansion into MedTech.

Click to open →

India's Alkem Labs unit to buy up to 55% of Occlutech for $118 million

BENGALURU, Feb 13 (Reuters) - Alkem Laboratories' medical devices unit will buy up to a 55% stake in Switzerland's Occlutech Holding for 99.4 million euros ($118 million), the Indian pharma company

Click to open →

Alkem Laboratories Ltd (BOM:539523) Q2 2026 Earnings Call Highlights: Record Revenue and ...

Alkem Laboratories Ltd (BOM:539523) reports a robust 17.2% YoY revenue growth, driven by strong US sales and domestic market leadership, while navigating operational expenses and GST impacts.

Click to open →

India's JK Paper logs eighth straight quarterly profit decline as wood costs pinch

(Reuters) -Indian paper and packaging board maker JK Paper posted its eighth consecutive quarter of profit fall on Monday, as the rising cost of wood pressured margins.

Click to open →

Enzene Biosciences forays into the US with new $50m Hopewell facility

Spanning over 7,430sqm, the new facility reinforces its commitment to supporting pharmaceutical innovation and supply chain resilience across North America.

Click to open →